Document Detail


Effect of moricizine hydrochloride in reducing chronic high-frequency ventricular arrhythmia: results of a prospective, controlled trial.
MedLine Citation:
PMID:  6367416     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The antiarrhythmic efficacy of moracizin HCl (Ethmozine), a new oral phenothiazine derivative, was evaluated in 20 patients with chronic high-frequency ventricular arrhythmia confirmed by multiple ambulatory electrocardiographic recordings. Comparison with 72 +/- 24 hours (+/- standard deviation) of ambulatory recordings on moracizin treatment (average dose 295 +/- 58 mg 3 times daily or 9.8 +/- 1.0 mg/kg/day) was made. Maximal treadmill exercise provocation of arrhythmia and echocardiographic studies to detect effects on left ventricular function were also compared. The group had an average of 378 +/- 97 ventricular premature beats (VPBs) per hour while receiving placebo, with a mean VPB grade of 3.4 +/- 1.1 (modified Lown). When the patients received moracizin HCl, VPB frequency was reduced 53% (p less than 0.01), to a mean VPB grade of 2.2 +/- 1.4 (p less than 0.05). Seventy percent of the patients (14 of 20) showed a reduction in VPB frequency that exceeded the maximal expected variation; in 3 the frequency did not change and in 3 it increased with moracizin HCl. Resting electrocardiographic changes consisted of modest prolongations of PR interval (0.03 second) and QRS duration (0.02 second); however, QT prolongation was not observed. Heart rate and blood pressure at rest and peak exercise, exercise-related arrhythmia, exercise durations and echocardiographic measures of left ventricular function were unchanged by moracizin HCl compared with placebo. Side effects of moracizin++ HCl at these dosages were minimal (diarrhea in 1 patient, dizziness in 1 and diaphoresis in 1), although 2 patients tested at higher dosages had sustained ventricular tachycardia that may have been related to moracizin HCl.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
S N Singh; R DiBianco; J S Gottdiener; R Ginsberg; R D Fletcher
Related Documents :
2417856 - The surdo-cardiac syndrome.
10090226 - Left ventricular ischemia due to coronary stenosis as an unexpected treatable cause of ...
18175856 - Relationship between electrocardiographic rr and qt interval variabilities and indices ...
7997556 - Trisomy 13 syndrome: prenatal us findings in a review of 33 cases.
2037816 - Evaluation of a newly devised three-lead holter recording during treadmill testing in t...
2311596 - Reduction of saliva immunoglobulin levels by swim training.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  The American journal of cardiology     Volume:  53     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1984 Mar 
Date Detail:
Created Date:  1984-04-13     Completed Date:  1984-04-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  745-50     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anti-Arrhythmia Agents / adverse effects,  therapeutic use*
Arrhythmias, Cardiac / drug therapy*
Chronic Disease
Clinical Trials as Topic
Echocardiography
Electrocardiography
Exercise Test
Heart / physiopathology
Humans
Male
Middle Aged
Moricizine
Phenothiazines / adverse effects,  therapeutic use*
Prospective Studies
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Phenothiazines; 31883-05-3/Moricizine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Randomized double-blind comparison of gallopamil and propranolol in stable angina pectoris.
Next Document:  Effects of diuretic therapy in low-, normal- and high-renin isolated systolic systemic hypertension.